NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - March 10, 2025) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company') is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange ('TSXV'). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone's leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone's strong market performance and strategic advances in the past year including 110% share price appreciation and 209% market cap growth.
The TSX Venture 50™ recognizes the top 50 performing issuers out of the 1,605 i listed issuers on the TSXV, across all sectors. Each company recognized is evaluated and chosen based on a combination of metrics including one year share price appreciation and market capitalization growth. In 2024, the 50 selected companies delivered an impressive average share price appreciation of 207% ii demonstrating strong investor confidence in high-growth enterprises.
'We are deeply honored to be recognized as a TSX Venture 50™ company. This reflects our unwavering commitment to advancing exosome-based therapies and creating long-term value for our shareholders,' said Dr. Lior Shaltiel, CEO of NurExone. 'It's a testament to the growing investor confidence in our mission to revolutionize regenerative medicine, the strength of our scientific breakthroughs, and the dedication of our talented team.'
Key milestones driving NurExone's success include significant progress in the development of ExoPTEN, the Company's proprietary exosome therapy for acute spinal cord injuries, as well as NurExone's establishment of its U.S. subsidiary, Exo-Top Inc., which accelerates its exosome production capabilities and advancement of their clinical pipeline. These efforts will help position NurExone as a leader in the rapidly growing field of exosome-based therapies.
The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated internationally across Europe, South America, Africa, and beyond iii, further highlighting the global impact of TSXV-listed firms.
Yoram Drucker, Chairman of NurExone, added 'being recognized by the TSX Venture 50™ is a significant milestone for NurExone, highlighting our strong financial performance and growth trajectory. We look forward to continuing our success as we expand our presence in the U.S. and explore new listing opportunities.'
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets [iv]. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: [email protected]
Oak Hill Financial Inc.
2 Bloor Street, Suite 2900
Toronto, Ontario M4W 3E2
Investor Relations - Canada
Phone: +1-647-479-5803
Email: [email protected]
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Allele Capital Partners
Investor Relations - U.S.
Phone: +1 978-857-5075
FORWARD-LOOKING STATEMENTS
This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company's advancing exosome-based therapies and creating long term value for shareholders; growing investor confidence in the Company's mission; Exo-Top Inc. accelerating its exosome production capabilities and advancing its clinical pipeline; the Company becoming a leader in the field of exosome-based therapies; the continued success of the Company; the Company expanding its presence in the U.S. and exploring new listing opportunities; the Company completing clinical trials in the U.S. and Europe; the Company's future plans and expectations; growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone advancing its development pipeline; NurExone's focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology offering solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications.
These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will advance exosome-based therapies and create long term value for shareholders; there being growing investor confidence in the Company's mission; Exo-Top Inc. will accelerate its exosome production capabilities and advance its clinical pipeline; the Company will become a leader in the field of exosome-based therapies; the Company will continue to succeed; the Company will expand its presence in the U.S. and explore new listing opportunities; the Company will complete clinical trials in the U.S. and Europe; there will be growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone will advance its development pipeline; NurExone will continue to focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology will offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, and on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; the Company's inability to expand into further studies; Exo-Top not have the intended benefits on the Company and/or its business; the Company be unable to advance exosome-based therapies and/or create long term value for shareholders; investor confidence in the Company's mission deteriorating; the Company not becoming a leader in the field of exosome-based therapies; the Company being unable to expand its presence in the U.S. and/or explore new listing opportunities; the Company being unable to initiate and/or complete clinical trials in the U.S. and Europe; clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas deteriorating; NurExone being unable to advance its development pipeline; NurExone being unable to focus on developing regenerative exosome-based therapies for central nervous system injuries; the NurExone platform technology being unable to offer solutions to companies interested in quality exosomes and/or minimally invasive targeted delivery systems for other indications; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's annual information form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Empress Grants Stock Options and Equity Incentives
VANCOUVER, BC / / June 6, 2025 / Empress Royalty Corp. (TSXV:EMPR)(OTCQX:EMPYF) ("Empress Royalty" or the "Company") announces that the Board of Directors has approved the granting of 1,400,000 incentive stock options (the "Options") to purchase an aggregate of 1,400,000 common shares (the "CommonShares") of the Company to certain directors, officers, employees, and consultants of the Company. Each Option is exercisable into one Common Share at an exercise price of $0.68, being the closing market price of Empress' common shares on June 6, 2025. The Options will vest as to one-third on the date of grant, one-third one year from the date of grant, and one-third two years from the date of grant and will expire on June 6, 2030. All stock option grants will be governed by the Company's Stock Option Plan which was approved by the shareholders of the Company at its last annual meeting of shareholders held on June 26, 2024. In addition, the Board of Directors has also approved the granting of 1,750,000 restricted share units ("RSUs") and 650,000 deferred share units ("DSUs") to certain directors, officers and consultants of the Company. Each of the RSUs and DSUs will vest equally over two years, with the first vesting date occurring June 6, 2026. Upon vesting, each RSU and DSU represents the right to receive one common share in the capital of the Company in accordance with the Company's Equity Incentive Plan, which was last approved by the shareholders of the Company at its annual meeting of shareholders held on September 28, 2022. ABOUT EMPRESS ROYALTY CORP. Empress is a global royalty and streaming creation company providing investors with a diversified portfolio of gold and silver investments. Empress has built a portfolio of precious metal investments and is actively investing in mining companies with development and production stage projects who require additional non-dilutive capital. The Company has strategic partnerships with Endeavour Financial and Terra Capital which allow Empress to not only access global investment opportunities but also bring unique mining finance expertise, deal structuring and access to capital markets. Empress is looking forward to continuously creating value for its shareholders through the proven royalty and streaming models. ON BEHALF OF EMPRESS ROYALTY CORP. Per: Alexandra Woodyer Sherron, CEO and President For further information, please visit our website at or contact us by email at info@ or by phone at +1.604.331.2080. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. The information contained herein includes "forward-looking statements" and "forward looking information" as defined under applicable Canadian securities laws ("forward-looking statements"). Forward-looking statements and information can generally be identified by the use of terms such as "may", "will", "should", "expect", "intend", "estimate" ,"continue", "believe", "plans", "anticipate" or similar terms. Forward-looking information and statements include, but are not limited to, statements with respect to the activities, events or developments that Empress Royalty Corp. ("Empress" or the "Company") expects or anticipates will or may occur in the future, including those regarding future growth and ability to create new streams or royalties, the development and focus of the Company , its acquisition strategy, the plans and expectations of the operators of the projects underlying its interests, including the proposed advancement and expansion of such projects; the results of exploration, development and production activities of the operators of such projects; and the Company's expectations regarding future revenues. Forward-looking information and statements are based on the then current expectations, beliefs, assumptions, estimates and forecasts about Empress's business and the industry and markets in which it operates. Forward-looking information and statements are made based upon numerous assumptions and although the assumptions made by the Company in providing forward-looking information and statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate. Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Empress to differ materially from any projections of results, performances and achievements of Empress including, without limitation, any inability of the operators of the properties underlying the Company's royalty and stream interests to execute proposed plans for such properties or to achieve planned development and production estimates and goals, risks related to the operators of the projects in which the Company holds interests, including the successful continuation of operations at such projects by those operators, risks related to exploration, development, permitting, infrastructure, operating or technical difficulties on any such projects, risks related to international operations, government relations and environmental regulation, uncertainty relating to the availability and costs of financing needed in the future and the Company's ability to carry out its growth plans as well as the impact of the COVID-19 pandemic and other related risks and uncertainties. For a discussion of important factors which could cause actual results to differ from forward-looking statements, refer to the annual information form of Empress for the year ended December 31, 2024 and its other publicly filed documents under its profile at Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and statements, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information and statements. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws. Disclosure relating to properties in which Empress holds royalty or stream interests is based on information publicly disclosed by the owners or operators of such properties. The Company generally has limited or no access to the properties underlying its interests and is largely dependent on the disclosure of the operators of its interests and other publicly available information. The Company generally has limited or no ability to verify such information. Although the Company does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. In addition, certain information publicly reported by operators may relate to a larger property than the area covered by the Company's interest, which often may only apply to a portion of the overall project area or applicable mineral resources or reserves. SOURCE: Empress Royalty Corp. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
a day ago
- Business Upturn
Draganfly Announces Additional Exercise Of Over-Allotment Option
Saskatoon, SK., June 06, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) ('Draganfly' or the 'Company'), a drone solutions, and systems developer, today announced that further to the closing of the Company's US$3.6 million underwritten public offering on May 5, 2025 (the 'Offering'), Maxim Group LLC, as underwriter and sole book-running manager, has partially exercised their over-allotment option to purchase an additional 100,000 common shares at the price of US$2.09 per share for aggregate gross proceeds of US$209,000 prior to deducting underwriter discounts and commissions. As previously announced, Draganfly intends to use the net proceeds from the Offering for general corporate purposes, including to fund its capabilities to meet demand for its new products including growth initiatives and/or for working capital requirements including the continuing development and marketing of the Company's core products, potential acquisitions and research and development. The Offering was made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No. 333-271498) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission ('SEC') on July 5, 2023 and the Company's Canadian short form base shelf prospectus dated June 30, 2023 (the 'Base Shelf Prospectus'). Draganfly offered and sold the securities in the United States only. No securities were offered or sold to Canadian purchasers. A final prospectus supplement and accompanying Base Shelf Prospectus relating to the Offering and describing the terms thereof has been filed with the applicable securities commissions in the Canadian provinces of British Columbia, Saskatchewan and Ontario, and with the SEC in the United States and is available for free by visiting the Company's profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at or the SEC's website at as applicable. Copies of the final prospectus supplements and accompanying Base Shelf Prospectus relating to the Offering may be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at [email protected] . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Draganfly Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) is a pioneer in drone solutions, AI-driven software, and robotics. With over 25 years of innovation, Draganfly has been at the forefront of drone technology, providing solutions for public safety, agriculture, industrial inspections, security, mapping, and surveying. The Company is committed to delivering efficient, reliable, and industry-leading technology that helps organizations save time, money, and lives. Media Contact [email protected] Company Contact Email: [email protected] Forward Looking Statements Certain statements contained in this news release may constitute 'forward-looking statements' or 'forward-looking information' within the meaning of applicable securities laws. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown. In this news release, such forward-looking statements include, but are not limited to, statements regarding the intended use of proceeds of the Offering. Actual future events may differ from the anticipated events expressed in such forward-looking statements. Draganfly believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and Draganfly is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable securities laws. Investors are cautioned not to unduly rely on these forward-looking statements and are encouraged to read the Offering documents, as well as Draganfly's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR+ at and on EDGAR at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
a day ago
- Yahoo
Primary Hydrogen Announces Renewal of Marketing Agreement
Calgary, Alberta--(Newsfile Corp. - June 6, 2025) - Primary Hydrogen Corp. (TSXV: HDRO) (FSE: 83W0) (OTCQB: HNATF) (the "Company" or "Primary") is pleased to announce the extension of its strategic marketing agreement (the "Services Agreement") with Euro Digital Media Ltd. ("Euro Digital") (address 71-75 Shelton Street, Covent Garden, London UK WC2H 9JQ) previously announced on November 27, 2024, March 28, 2025 and May 7, 2025. Under the terms of the Services Agreement, Euro Digital creates campaigns, ad groups, text ads, display ads, performs detailed keyword research, setup and manages remarketing campaigns, optimize keyword options, coordinates online advertisers and marketers corresponding to online marketing targets, creates landing pages for ad campaigns and generally bring attention to the business of the Company. The Company has renewed the Services Agreement and agreed to pay Euro Digital a fee of USD $100,000 for continuation of the ongoing services, inclusive of third-party costs. The renewal of the services under the Services Agreement will commence on or about June 10, 2025, and continue until the earlier of (a) a two-month term, and (b) exhaustion of the marketing budget. The principal of Euro Digital is Harry Kundan. The Company will not issue any securities to Euro Digital as compensation for its marketing services. As of the date hereof, to the Company's knowledge, Euro Digital (including its principal) does not own any securities of the Company and has an arm's length relationship with the Company. The renewal of the Services Agreement is subject to approval of the TSX Venture Exchange. About Primary Hydrogen Corp. Primary Hydrogen is dedicated to the exploration and development of natural hydrogen resources. With over 740 acres in the U.S. and 230 square kilometers across Canada, the Company's portfolio includes the Blakelock, Hopkins, Mary's Harbour, Point Rosie, Crooked Amphibolite, Coquihalla, and Cogburn projects. Primary also holds the Arthur Lake copper project in British Columbia and has an option to acquire a 75% interest in a hydrogen-REE project known as Wicheeda North, also located in British Columbia. -- FOR FURTHER INFORMATION PLEASE CONTACT: Ben Asuncion, CEO, Primary Hydrogen Corp. at ben@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. The forward-looking statements herein are made as of the date of this news release only. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes statements with respect to the provision of services by Euro Digital to the Company. Although the Company believes, in light of the experience of their officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this news release are reasonable, undue reliance should not be placed on them because the parties can give no assurance that such statements will prove to be correct. Such statements and information reflect the current view of the Company. There are risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this news release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including, but not limited to, the risk that the TSX Venture Exchange will not approve the Service Agreement, stock market volatility and capital market fluctuations, general market and industry conditions, as well as those risk factors discussed in the Company's most recently filed management's discussion and analysis filed under the Company's SEDAR+ profile at Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. To view the source version of this press release, please visit Sign in to access your portfolio
